Merck & Co. (NYSE: MRK) – known as MSD outside the United States and Canada – and Ridgeback Biotherapeutics announced on Friday that molnupiravir (MK-4482, EIDD-2801), an oral antiviral in clinical trials, significantly reduced the risk of hospitalization or death based on the results of the phase III interim analysis of the MOVe-OUT trial conducted on non-hospitalized adult patients at risk with mild or moderate COVID-19.
Covid, large companies ready to choose therapies instead of vaccines
The possible anti Covid pill has gone indigestible to Big Pharma. As the Truth points out, on Friday the Merck company closed with a strong rise on Wall Street, where it gains 8.4%, in what is the largest increase in five years. But Merck’s jump was accompanied by Pfizer’s 0.26% decline, Moderna’s -11.37% and Novavax’s -12.21%. According to what La Verità writes, large companies are ready to throw themselves into therapies, while Merck itself has announced the acquisition of Acceleron, used in anticancer immunotherapies.